Quetiapine augmentation of a serotonin reuptake inhibitor in treatment resistant obsessive-compulsive disorder: a multi-site, placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83050762

Enrollment

Registered

2005-01-13

Start date

2002-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder Mental and Behavioural Disorders Obsessive-compulsive disorder

Interventions

Placebo-controlled, double-blind, flexible-dose augmentation with quetiapine of a serotonin reuptake inhibitor maintaned at the stable maximum tolerated dose.

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with obsessive-compulsive disorder who failed at least one trial (12 weeks duration, of which six weeks at maximum tolerated dose) of a serotonin reuptake inhibitor.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration.	—

Secondary

Measure	Time frame
Not provided at time of registration.	—

Countries

Canada, South Africa

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026